
Opinion|Videos|February 9, 2026
The Role of Tumor Burden on Treatment Selection in EGFR-Mutated NSCLC
Author(s)Narjust Florez, MD
High tumor burden lung cancer demands fast action: start chemo while awaiting biomarkers, then add osimertinib for rapid symptom relief.
Advertisement
Episodes in this series

Narjust Florez, MD, explores how baseline tumor burden may influence therapeutic decision-making in EGFR-mutated non–small cell lung cancer (NSCLC). Florez discusses associations between disease volume, symptom burden, and urgency of response when considering systemic therapy options. She highlights how tumor burden can help frame risk–benefit discussions, particularly when balancing rapid disease control against potential toxicity.
Advertisement
Related to this article

The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.

The FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.

Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training
Christine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.

The FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.

The FDA has approved neladalkib for previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
3
Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC
4
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
5

